In the neoadjuvant setting, PIK3CA mutations do not appear to be associated with altered sensitivity to preoperative chemotherapy with anthracyclines and taxanes, although mutations in exon 9 are associated with a higher rate of node-negative residual disease, especially in the subgroup of patients with estrogen receptor (ER)-positive BC [17]. This evidence concerns the gene PIK3CA and breast cancer.